Drug Database
CE

cefalexin (Panixine DisperDose / Panixine DisperDose)

✓ Approved

Ranbaxy Laboratories Limited · 小分子 · 小分子

什么是 cefalexin?

cefalexin 是一种小分子,由Ranbaxy Laboratories Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Panixine DisperDose, Panixine DisperDose
公司Ranbaxy Laboratories Limited
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

cefalexin 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsUrinary tract infection✓ Approved
Infections and infestationsViral upper respiratory tract infection✓ Approved

相关研究文献

PubMedCureus2026-09-11

Oral Manifestations of Juvenile Behçet Syndrome: A Case Report and Mini-Review of the Literature.

El Omari Safaa S, Barhoud Oumaima O, Elarabi Samira S, Bensouda Sana S

Behçet's disease is a chronic, relapsing, multisystem inflammatory vasculitis characterized by a broad spectrum of mucocutaneous and systemic manifestations. Oral ulcerations are often the earliest and most frequent clinical feature, playing a central role in diagnosis, particularly in pediatric patients, in whom the disease remains uncommon and its diagnosis is frequently delayed. We report the case of a boy aged 11 years and 6 months with juvenile Behçet syndrome who presented with recurrent oral aphthous ulcerations, including an 8-mm ulcer on the left lateral border of the tongue and a 5-mm ulcer on the external surface of the upper lip, along with poor oral hygiene and generalized gingival inflammation. The patient had a history of arthralgia and was receiving colchicine (1 mg/day). Oral management consisted of reinforcement of oral hygiene and dietary measures, full-mouth scaling, and topical treatment with corticosteroids and propolis-based therapy. At the 10-day follow-up, complete healing of the initial oral lesions and marked improvement in gingival inflammation were observed, although new aphthous ulcers developed at different intraoral sites, consistent with the relapsing nature of the disease. This case highlights the importance of early recognition of oral manifestations in Pediatric Behçet's Disease (PEDBD) and emphasizes the key role of pediatric dentists in facilitating diagnosis, multidisciplinary management, and long-term follow-up. Appropriate oral care may contribute to improved symptom control, enhanced quality of life, and the prevention of oral complications.

PMID 42724917
阅读全文 →
PubMedJournal of palliative medicine2026-09-11

Methylene Blue Oral Rinse for Cancer-Related Oral Mucositis Pain #540.

S Carlson Erik E, Arnold Robert R

PMID 42722988
阅读全文 →
PubMedClinical case reports2026-09-11

Restoration of Functional Oral Intake After Proximal Gastrectomy Using an Individualized Risk-Adapted Multidisciplinary Approach: A Case Report.

Ito Shogo S, Takada Hirokazu H, Shibata Kazuhiro K, Yamamoto Hidekazu H

Dental rehabilitation restored functional oral intake after gastrectomy, followed by long-term improvement in BMI and stabilization of hematologic, iron-status, and metabolic parameters. A risk-adapted multidisciplinary approach combining medical optimization and oral rehabilitation may benefit selected patients with post-gastrectomy malnutrition.

PMID 42724490
阅读全文 →
PubMedFrontiers in dental medicine2026-09-11

Oral dysbiosis in children with renal failure: a systematic review.

Ruiz-Roca Juan Antonio JA, Pecci-Lloret María Pilar MP, Romano Antonio A, Carinci Francesco F et al.

The oral microbiome plays an important role in maintaining host homeostasis and may interact with systemic diseases through the oral-systemic axis. Chronic kidney disease (CKD) in childhood is associated with chronic inflammation, metabolic alterations, and immune dysfunction, which may influence microbial ecosystems. While intestinal dysbiosis has been widely studied in paediatric CKD, alterations in the oral microbiome remain less well understood. The aim of this study was to qualitatively synthesize evidence on oral microbiome alterations in children and adolescents with CKD compared with systemically healthy controls. A systematic review was conducted according to PRISMA 2020 and registered in PROSPERO (CRD420261334000). PubMed, Scopus, Web of Science, Cochrane, and SciELO were searched (February 24, 2026). Eligible studies included participants aged 0-18 years with CKD (any stage), dialysis, or kidney transplantation and a healthy control group. Risk of bias was assessed using JBI and ROBINS-I v2 tools. From 109 records, 7 studies were included. Most used saliva, tongue/oral swabs, or dental plaque, and 16S rRNA sequencing was the most frequent method. Five studies reported oral dysbiosis in CKD, including severe dysbiosis grades in adolescents with end-stage disease, while two studies reported no significant differences versus controls. Findings on individual taxa were inconsistent across studies, likely due to heterogeneity in renal phenotype, oral niche sampled, and analytical methods. Evidence suggests that salivary biochemical alterations (notably urea and pH) and inflammatory burden may influence microbial composition, whereas the tongue microbiome may show relative ecological stability in some paediatric cohorts. Children and adolescents with CKD may present oral microbiome alterations, but current evidence is limited by methodological heterogeneity and moderate-to-high risk of bias. Standardized sampling and longitudinal multicentre studies are needed to determine robust microbial signatures and their value as non-invasive biomarkers in paediatric nephrology. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261334000.

PMID 42723799
阅读全文 →
PubMedJournal of thoracic disease2026-09-11

Thoracic surgery in the era of targeted and/or oral therapies for hematologic malignancies: a retrospective case series of postoperative hemorrhagic complications.

Stasiak Florent F, Novy Emmanuel E, Jacquet Caroline C, Streit Arthur A et al.

Patients treated with oral or targeted therapies for hematologic malignancies represent a growing population among candidates for thoracic surgery. These treatments, along with the underlying hematologic disorders, can impair hemostasis and increase perioperative bleeding risk. However, no specific recommendations currently exist for their perioperative management. The aim of this review is to explore potential factors contributing to perioperative bleeding in patients with hematologic malignancies receiving oral or targeted therapies who underwent anatomical lung resection. We conducted a retrospective monocentric case series of seven patients with hematologic malignancies receiving oral chemotherapy who underwent major lung resection for lung cancer at the University Hospital of Nancy between 2024 and 2025. Data regarding intraoperative blood loss, postoperative drainage, occurrence of hemothorax, transfusion, and need for surgical revision were collected. Postoperative hemothorax occurred in 71.4% (5/7) of patients, and 42.9% required blood transfusion. Two patients (28.6%) required surgical revision for postoperative bleeding. Median intraoperative blood loss was 100 mL (80-1,000 mL), and median postoperative day-1 drainage was 1,040 mL (130-2,000 mL). Notably, the two patients who discontinued oral chemotherapy before surgery did not experience postoperative bleeding. An unexpectedly high incidence of postoperative hemorrhagic complications was observed in this small cohort of patients receiving oral or targeted therapies for hematologic malignancies. Although causality cannot be established, these findings support careful multidisciplinary perioperative assessment and warrant further investigation in larger studies.

PMID 42724350
阅读全文 →
PubMedAnnals of medicine and surgery (2012)2026-09-11

Effect of oral propranolol on clinical findings and complications in retinopathy of premature infants: a randomized controlled trial.

Noorizade Sama S, Ghorbani Lida L, Iranpoor Sohrab S, Najafi Amin A et al.

This study aimed to investigate the efficacy and safety of oral propranolol in reducing the progression of retinopathy of prematurity (ROP) and its associated complications. This randomized controlled trial was conducted on preterm infants with ROP. Participants were randomly assigned to either a propranolol group receiving oral propranolol (0.5 mg/kg every 8 hours) or a control group receiving distilled water. The primary outcome was the duration of complete retinal vascularization. Secondary outcomes included ROP stage and severity, vital signs, and potential complications (hypoglycemia, bradycardia, and hypotension). A total of 61 infants (31 in the propranolol group and 30 in the control group) were included in the final analysis. There was no significant difference in the distribution of ROP stage and severity between the groups (P = 0.40). However, the duration of complete retinal vascularization was significantly shorter in the propranolol group [76.9 standard deviation (SD) = 11.06) days] compared to the control group [89.6 (SD = 9.6) days] (P < 0.001). While hypotension was more frequent in the propranolol group (45.1%) compared to the control group (26.7%), this difference was not statistically significant (P = 0.18). Oral propranolol significantly reduced the time required for retinal vascularization in infants with ROP. The treatment was well-tolerated, with no serious adverse effects such as hypoglycemia or bradycardia. Although hypotension was more common in the propranolol group, the difference was not statistically significant. These findings suggest that oral propranolol may be a safe and effective adjunct therapy for ROP.

PMID 42724763
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多cefalexin